20
What are the latest advances in Plasminogen Deficiency (PLGD)?
Here you can see the latest advances and discoveries made regarding Plasminogen Deficiency (PLGD).
Prometic Life Sciences is developing a new plasminogen replacement therapy for congenital PLGD. Interim trial results from a Phase 2/3 study in patients with congenital PLGD have demonstrated that plasminogen IV effectively resolved 90.9% of visible lesions within 12 weeks and no new lesions developed during this treatment period. Non-visible (systemic) lesions also showed improvement. Plasminogen IV therapy has been shown to be well tolerated and safe. (C. Nakar, A. Shapiro et al; ISTH, 2017). Plasminogen replacement therapy has received orphan drug designation and priority review by the FDA. Official FDA review is ongoing at the time of this writing.
Posted Aug 9, 2017 by jodoinjulie 2000
